• Users Online: 1269
  • Print this page
  • Email this page

    Article Cited by others

REVIEW

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase

Woo Peter Y. M., Li Yi, Chan Anna H. Y., Ng Stephanie C. P., Loong Herbert H. F., Chan Danny T. M., Wong George K. C., Poon Wai-Sang

Year : 2019| Volume: 2| Issue : 2 | Page no: 68-82

   This article has been cited by
 
1 Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
Federica Fabro, Martine L. M. Lamfers, Sieger Leenstra
Cancers. 2022; 14(3): 600
[Pubmed]  [Google Scholar] [DOI]
2 Ferroptosis Modulation: Potential Therapeutic Target for Glioblastoma Treatment
Izadora de Souza, Maria Carolina Clares Ramalho, Camila Banca Guedes, Isabeli Yumi Araújo Osawa, Linda Karolynne Seregni Monteiro, Luciana Rodrigues Gomes, Clarissa Ribeiro Reily Rocha
International Journal of Molecular Sciences. 2022; 23(13): 6879
[Pubmed]  [Google Scholar] [DOI]
3 Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas
Shalini Sundramurthi Chelliah,Ervin Ashley Lourdes Paul,Muhamad Noor Alfarizal Kamarudin,Ishwar Parhar
Molecules. 2021; 26(4): 1169
[Pubmed]  [Google Scholar] [DOI]
4 From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Xueyuan Sun,Sevin Turcan
Cells. 2021; 10(5): 1225
[Pubmed]  [Google Scholar] [DOI]
5 Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
Manendra Singh Tomar,Ashok Kumar,Chhitij Srivastava,Ashutosh Shrivastava
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2021; : 188616
[Pubmed]  [Google Scholar] [DOI]
6 Aggressive pituitary tumours and pituitary carcinomas
Gérald Raverot,Mirela Diana Ilie,Hélène Lasolle,Vincent Amodru,Jacqueline Trouillas,Frédéric Castinetti,Thierry Brue
Nature Reviews Endocrinology. 2021;
[Pubmed]  [Google Scholar] [DOI]
7 Radiotherapy-induced glioblastoma: distinct differences in overall survival, tumor location, pMGMT methylation and primary tumor epidemiology in Hong Kong chinese patients
Peter Y. M. Woo,Jennifer W. Y. Lee,Sandy W. Lam,Jenny K. S. Pu,Danny T. M. Chan,Calvin H. K. Mak,Jason M. K. Ho,Sui-To Wong,Yin-Chung Po,Michael W. Y. Lee,Kwong-Yau Chan,Wai-Sang Poon
British Journal of Neurosurgery. 2021; : 1
[Pubmed]  [Google Scholar] [DOI]
8 Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?
Chibueze D. Nwagwu,David C. Adamson
Expert Opinion on Pharmacotherapy. 2021; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Temozolomide Induces Endocytosis of EGFRvIII via p38-Mediated Non-canonical Phosphorylation in Glioblastoma Cells
Ratna Dini Haryuni, Tomohiro Tanaka, Jun-ichiro Takahashi, Iimi Onuma, Yue Zhou, Satoru Yokoyama, Hiroaki Sakurai
Biological and Pharmaceutical Bulletin. 2021; 44(11): 1681
[Pubmed]  [Google Scholar] [DOI]
10 Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma
Margaux Fresnais, Sevin Turcan, Dirk Theile, Johannes Ungermann, Yasmin Abou Zeed, Joshua Raoul Lindner, Marius Breitkopf, Jürgen Burhenne, Walter E. Haefeli, Rémi Longuespée
Biomedicines. 2021; 10(1): 1
[Pubmed]  [Google Scholar] [DOI]
11 Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms
Silvia Paukovcekova,Jan Skoda,Jakub Neradil,Erika Mikulenkova,Petr Chlapek,Jaroslav Sterba,Des R. Richardson,Renata Veselska
Cancers. 2020; 12(12): 3781
[Pubmed]  [Google Scholar] [DOI]
12 Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries
Clarissa Ribeiro Reily Rocha,Alexandre Reily Rocha,Matheus Molina Silva,Luciana Rodrigues Gomes,Marcela Teatin Latancia,Marina Andrade Tomaz,Izadora de Souza,Linda Karolynne Seregni Monteiro,Carlos Frederico Martins Menck
Cells. 2020; 9(12): 2573
[Pubmed]  [Google Scholar] [DOI]

 

Read this article